Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. Show more

Location: 47 Hulfish Street, Princeton, NJ, 08542, United States | Website: https://amicusrx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

2.051B

52 Wk Range

$5.51 - $12.65

Previous Close

$6.66

Open

$6.72

Volume

3,250,701

Day Range

$6.70 - $7.01

Enterprise Value

2.264B

Cash

231M

Avg Qtr Burn

-11.41M

Insider Ownership

0.72%

Institutional Own.

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Details Pompe Disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Galafold (migalastat) Details Fabry disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-GTX-501 Details Batten Disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AT-GTX-502 Details Batten Disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.